Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 53%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

Analysis of tumor biopsies from the ZUMA-1 trial identifies pre-treatment T cell-related characteristics that are associated with clinical response & neurologic toxicity following anti-CD19 CAR-T cell therapy in patients with large B cell lymphomas

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Extended Data Fig. 1 Characterization of ZUMA-1 tumour biopsy specimens analysed in this study.

a, Heatmap of gene expression measured by PanCancer Immune Profiling panel in FFPE tumour biopsy specimens pretreatment or posttreatment from Zuma 1 patients with high or low tumour burden at pretreatment. Among the genes with significant differential expression between pre and post treatment , shown genes were selected according to their belonging to a specific TME related signature.

Extended Data Fig. 6 Correlative studies of Immunosign 21 score with cell subsets across 3 independent datasets.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in LAW

Law Law Latest News, Law Law Headlines